LPL Financial’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.7M Buy
112,240
+17,496
+18% +$1.86M ﹤0.01% 1866
2025
Q4
$9.77M Buy
94,744
+56,479
+148% +$5.49M ﹤0.01% 1948
2025
Q3
$3.46M Sell
38,265
-9,963
-21% -$873K ﹤0.01% 2807
2025
Q2
$4.24M Sell
48,228
-258
-0.5% -$22.4K ﹤0.01% 2455
2025
Q1
$4.42M Sell
48,486
-8,887
-15% -$800K ﹤0.01% 2252
2024
Q4
$4.95M Sell
57,373
-35,154
-38% -$3.18M ﹤0.01% 2091
2024
Q3
$8.79M Buy
92,527
+5,225
+6% +$496K ﹤0.01% 1554
2024
Q2
$7.99M Sell
87,302
-5,991
-6% -$535K ﹤0.01% 1510
2024
Q1
$8.46M Buy
93,293
+24,580
+36% +$2.15M ﹤0.01% 1443
2023
Q4
$5.59M Buy
68,713
+2,964
+5% +$232K ﹤0.01% 1619
2023
Q3
$5.25M Buy
65,749
+24,850
+61% +$2M ﹤0.01% 1569
2023
Q2
$3.22M Sell
40,899
-3,704
-8% -$290K ﹤0.01% 1862
2023
Q1
$3.46M Sell
44,603
-65,952
-60% -$5.08M ﹤0.01% 1744
2022
Q4
$8.59M Buy
110,555
+37,806
+52% +$2.79M 0.01% 1113
2022
Q3
$4.89M Buy
72,749
+30,770
+73% +$2.27M ﹤0.01% 1394
2022
Q2
$3.23M Buy
41,979
+22,802
+119% +$1.78M ﹤0.01% 1680
2022
Q1
$1.53M Buy
19,177
+571
+3% +$43.7K ﹤0.01% 2250
2021
Q4
$1.43M Buy
18,606
+2,409
+15% +$179K ﹤0.01% 2354
2021
Q3
$1.18M Buy
16,197
+17
+0.1% +$1.27K ﹤0.01% 2486
2021
Q2
$1.18M Buy
16,180
+2,875
+22% +$205K ﹤0.01% 2431
2021
Q1
$918K Buy
13,305
+2,670
+25% +$184K ﹤0.01% 2464
2020
Q4
$707K Sell
10,635
-974
-8% -$62.4K ﹤0.01% 2461
2020
Q3
$722K Sell
11,609
-375
-3% -$23.7K ﹤0.01% 2182
2020
Q2
$746K Buy
11,984
+2,899
+32% +$175K ﹤0.01% 2068
2020
Q1
$494K Sell
9,085
-465
-5% -$28.6K ﹤0.01% 2114
2019
Q4
$613K Sell
9,550
-146
-2% -$8.8K ﹤0.01% 2197
2019
Q3
$553K Sell
9,696
-2,260
-19% -$129K ﹤0.01% 2181
2019
Q2
$701K Sell
11,956
-2,278
-16% -$132K ﹤0.01% 1990
2019
Q1
$864K Sell
14,234
-768
-5% -$45.4K ﹤0.01% 1751
2018
Q4
$822K Buy
15,002
+897
+6% +$54.3K ﹤0.01% 1685
2018
Q3
$908K Buy
14,105
+628
+5% +$39.1K ﹤0.01% 1737
2018
Q2
$795K Buy
13,477
+288
+2% +$16.7K ﹤0.01% 1792
2018
Q1
$750K Sell
13,189
-907
-6% -$54.2K ﹤0.01% 1827
2017
Q4
$836K Sell
14,096
-708
-5% -$40.6K ﹤0.01% 1665
2017
Q3
$855K Sell
14,804
-1,091
-7% -$61.9K ﹤0.01% 1549
2017
Q2
$939K Sell
15,895
-299
-2% -$16.9K ﹤0.01% 1416
2017
Q1
$884K Buy
16,194
+44
+0.3% +$2.39K 0.01% 1337
2016
Q4
$862K Sell
16,150
-55
-0.3% -$2.94K 0.01% 1320
2016
Q3
$928K Buy
16,205
+399
+3% +$23.9K 0.01% 1258
2016
Q2
$937K Sell
15,806
-14,924
-49% -$870K 0.01% 1218
2016
Q1
$1.76M Buy
30,730
+2,980
+11% +$176K ﹤0.01% 1276
2015
Q4
$1.79M Buy
27,750
+14,361
+107% +$927K 0.01% 1242
2015
Q3
$861K Buy
13,389
+104
+0.8% +$7.31K ﹤0.01% 1348
2015
Q2
$946K Sell
13,285
-662
-5% -$47.7K ﹤0.01% 1410
2015
Q1
$967K Sell
13,947
-317
-2% -$21.5K ﹤0.01% 1375
2014
Q4
$917K Buy
14,264
+1,170
+9% +$74.5K 0.01% 1369
2014
Q3
$823K Buy
13,094
+1,120
+9% +$69.4K ﹤0.01% 1403
2014
Q2
$743K Buy
11,974
+2,520
+27% +$150K ﹤0.01% 1531
2014
Q1
$552K Buy
9,454
+2,586
+38% +$146K ﹤0.01% 1665
2013
Q4
$365K Sell
6,868
-281
-4% -$14.2K ﹤0.01% 1965
2013
Q3
$345K Buy
7,149
+2,460
+52% +$117K ﹤0.01% 1909
2013
Q2
$213K Buy
+4,689
New +$217K ﹤0.01% 2161

Other funds holding PPH

LPL Financial's PPH Position: Q1 2026 in Review

LPL Financial increased its VanEck Pharmaceutical ETF (PPH) stake by 18% in Q1 2026, buying an estimated $1.86M and bringing the position to 112,240 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1866.

LPL Financial first reported a position in PPH in Q2 2013 and has held it in 52 quarters since. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

  • LPL Financial held 112,240 shares of VanEck Pharmaceutical ETF worth $11.7M as of Q1 2026.
  • LPL Financial bought 17,496 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $1.86M.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #1866 holding.
  • LPL Financial first reported a position in VanEck Pharmaceutical ETF in Q2 2013 and has held it in 52 quarters since.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.